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Granulocyte/macrophage colony-stimulating factor (GM-CSF)  ~ is one of a set 
of specific glycoproteins collectively known as colony-stimulating factors, which 
interact to control the growth and differentiation of hematopoietic cells (1-3). 
This polypeptide hormone stimulates the  proliferation of granulocyte/macro- 
phage precursor cells,  can  induce differentiation commitment in these precur- 
sors, and can, as well modulate the functional activity of mature granulocytes 
and macrophages (4-9). 
Recently, the  cloning of the  genes  encoding murine  GM-CSF  (10-12)  and 
human GM-CSF (12-14) and the subsequent expression in yeast of these recom- 
binant proteins (12)  has made possible a  more detailed study of the mode of 
action of these factors. As with other polypeptide hormones, GM-CSF appears 
to initiate its activity by binding to specific receptors on the plasma membrane 
of responding cells (15,  16). We have recently reported (16)  the use of purified 
recombinant murine GM-CSF, radiolabeled with 125I, tO characterize the kinetic 
parameters,  cellular distribution, and  molecular size  of the  receptor  for  this 
factor on murine cells of both myeloid and T  cell lineage. 
This paper  describes the  use of recombinant human GM-CSF, radiolabeled 
with  ~25I to high specific activity, to identify and characterize the receptor for 
this hormone on  both a  mature primary cell,  human neutrophils, and on  the 
promyelocytic leukemia cell  line,  HL-60.  We  show that the properties of the 
GM-CSF receptor exhibited by these two cell  populations are  very similar, in 
both cases characterized by a strikingly low number of receptors expressed per 
cell.  This  initial  characterization of the  receptor  for human  GM-CSF should 
begin  to  lay  the  groundwork  that  will  be  necessary  to  fully understand  the 
complex interactions of the human colony-stimulating factors, as well as allow an 
accurate assessment of their potential as therapeutic agents. 
Materials and Methods 
Cell  Preparations.  All  cell lines except  HL-60  were  grown  in  RPMI  1640 (Gibco 
Laboratories, Grand Island, NY) containing  10% FCS, penicillin (50 U/ml), streptomycin 
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(50 #g/ml), and glutamine (1  mM) with or without 5 x  10 -~ M 2-ME. The cell  line |1l~- 
60 (17)was grown with 20%, instead of 10%, FCS. 
Human neutrophils were purified from leukocyte layers (Portland Red ('ross, Portland, 
OR) with  Neutrophil  Isolation Medium (Packard  Instrument Co.,  Inc., Downers Grove, 
IL), essentially following the manufacturer's specifications. Briefly, four leukocyte layers 
were  diluted  to  350  ml  with  PBS,  and  35  ml  was  layered  on  15  ml  of Ficoll  (Sigma 
Chemical Co., St. Louis, MO) and centrifuged at 1,600 rpm for 15 rain.  From each tube, 
the polymorphonuclear and erythrocyte layers were retained, diluted to 40 ml with PBS, 
and 20 ml was layered on 10 ml of Neutrophil Isolation Medium and centrifuged at  1,200 
rpm  for 30 min.  The polymorphonuclear layers were retained,  washed once with  PBS, 
and contaminating erythrocytes were removed by a  1 rain lysis with lysing buffer (Packard 
Instrument Co., Inc.). Remaining polymorphonuclear cells were washed twice with PBS, 
resuspended  in  RPMI  1640, and maintained at 25°C until use.  Human monocytes were 
prepared as previously described (18). 
Murine neutrophils were purified from whole blood on Neutrophil  Isolation Medium, 
following the manufacturer's specifications. 
Hormone Preparations.  Nerve growth factor, fibroblast growth factor, and epidermal 
growth factor were obtained from Bethesda Research Labs (Gaithersburg,  MD). Human 
follicle-stimulating  hormone,  human  luteinizing  hormone,  human  thyroid-stimulating 
hormone, human growth hormone, and bovine insulin were obtained from Calbiochem- 
Behring (La Jolla, CA). 
Human  IL-2 was expressed  in,  and purified  from Escherichia col| and  provided via a 
collaborative research agreement between Immunex Corporation and Hoffman-La Roche 
Inc., Nutley, NJ. Colony-stimulating factor 2c~ (CSF-2c~) (IL-3) was purified to homogeneity 
from  medium  conditioned  by  PHA-stimulated  LBRM-33-5A4  cells,  as  previously  de- 
scribed (19). Human I L-1  was purified to homogeneity, as previously described (20), from 
medium conditioned by activated human macrophages (20).  Recombinant murine  GM- 
CSF was produced in a yeast expression system and purified to homogeneity from yeast- 
conditioned medium by reverse-phase HPLC as previously described (12,  16). 
Recombinant Human GM-CSF Pur~cation and Radiolabeling.  Recombinant human GM- 
CSF was produced in a yeast expression system and purified to homogeneity from yeast- 
conditioned medium by reverse-phase  HPLC (12,  D.  Urdal,  unpublished  data).  Briefly, 
yeast cells transformed with a plasmid containing the cDNA sequence encoding GM-CSF 
(I 2) under the control of the alcohol dehydrogenase 2 promoter and alpha factor leader, 
secrete  GM-CSF  into the  medium  at  levels of 5  mg/liter.  Medium  containing secreted 
recombinant GM-CSF was pumped directly onto a  Vydac C4 reverse-phase column and 
proteins were eluted from the column with a gradient of acetonitrile in 0.1% trifluoroac- 
etic acid. GM-CSF concentrations were determined by fluorescamine analysis (21) of the 
purified protein, with BSA as a standard. GM-CSF activity was measured in a human bone 
marrow colony assay, as previously described (12). 
Human recombinant GM-CSF was radiolabeled using the Enzymobead radioiodination 
reagent  (Bio-Rad  Laboratories,  Richmond,  CA), essentially  as previously described  for 
routine  recombinant  GM-CSF  (16).  Bioactivity of *251-GM-CSF was determined  in  the 
human bone marrow colony assay (12).  Labeled GM-CSF preparations were analyzed by 
gel fihration chromatography on Sephadex G-75 (Pharmacia Fine Chemicals, Piscataway, 
N  J) to test for the presence of high molecular weight aggregates. The specific activity of 
the  radiolabeled  GM-CSF  (generally  0.5-2  x  l015  cpm/mmol)  was  based  on  protein 
concentration, as determined by fluorescamine analysis and by assuming an 80% yield of 
~51-GM-CSF after separation on the G-25 column. 
Assay for Binding of vz51-GM-CSF to Intact Cells.  Binding assays were performed  by a 
phthalate  oil separation  method (22) essentially as described previously for murine  1251- 
GM-CSF (16). Sodium azide (0.2%) was included in all binding assays to inhibit internali- 
zation and degradation of J2~I-GM-CSF  by cells at  37°C. To verify that no degradation 
of ligand was occurring, aliquots were removed fi'om incubation mixtures maintained at 
37°(;  for  up  to  1 h  and  precipitated  on  Whatman  3  MM  paper  with  10%  TCA.  No PARK  ET  AL.  253 
FIGURE  1.  Characterization of ~251-GM-CSF by SDS-PAGE. ~2~I-GM-CSF (specific radioactiv- 
~s  ity,  10  cpm/mmol) was boiled for 3 rain in sample buffer containing 2% SDS and 5% 2-ME 
anct  10,000 cpm were applied to a  linear  10-20%  gradient gel.  Electrophoresis and autora- 
diography were then conducted as described in Materials and Methods. 
decrease in TCA precipitable counts was detected over this time period. Association and 
dissociation kinetic experiments were also conducted as preViously described (16). 
SDS-PAGE.  Samples were boiled for 3 min in sample buffer (0.06  M Tris-HCl, pH 
6.8, 2% SDS,  10% glycerol, 5% 2-ME), and analyzed on 10-20% gradient gels according 
to the stacking gel procedure of Laemmli (23).  Relative molecular weight markers (Mr) 
cytochrome  c,  12,300;  lactoglobulin  A,  18,367;  carbonic  anhydrase,  31,000;  OVA, 
46,000;  BSA, 69,000; phosphorylase B, 97,400; and  myosin, 200,000 methylated with 
[~4C]methyl label were from New England Nuclear (Boston, MA). After electrophoresis, 
gels were stained with Coomassie blue (0.25% in 25% isopropanol and 10% acetic acid), 
dried,  and  then exposed to  X-omat AR  film (Eastman  Kodak Co.,  Rochester, NY) at 
-70°C. 
Data Analysis.  Curve fitting of binding and kinetic data was done using RS/1  (Bolt, 
Beranek and  Newman  Software  Products  Corporation,  Boston,  MA),  a  commercially 
available data processing package running on a VAX  11/750 under the VMS operating 
system. Kinetic data were analyzed with functions that are single or sums of exponential 
terms as described elsewhere (24,  25),  binding data  were analyzed using  an  equation 
describing simple bimolecular binding (22),  and inhibition data were analyzed with an 
equation for competitive inhibition between two ligands for one type of site (26). 
Results 
Radiolabeling  of Human  GM-CSF.  Recombinant  human  GM-CSF  was  iodi- 
nated to high  specific activity with  the  use of the Enzymobead radioiodination 
reagent  from  Biorad  Laboratories.  Fig.  1  illustrates  an  autoradiograph  of a 
typical iodinated GM-CSF preparation, where the major species after iodination 
had  an  apparent  molecular  weight  of 21,000  on analysis  by SDS-PAGE.  GM- 
CSF protein concentrations were determined by the Fluorescamine protein assay 
and  the  radiolabeled  preparations  were calculated to  have specific activities  in 
the  range  of  1015 cpm/mmol.  When  tested  in  a  human  bone  marrow  colony 
assay,  radiolabeled  GM-CSF  preparations  were  found to retain >50%  of their 
biological activity.  Preparations  of 1zSI-GM-CSF  were  stable  for at  least  1  mo 254  GRANUI.OCYTE/MACROPHAGE COLONY-STIMULATING  FACTOR  RECEP'I()R 
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FIGURE  2.  Association and  dissociation  kinetics of I~SI-GM-CSF with neutrophils at  37°C. 
(A) Neutrophils (6.67  X  10 7 cel[s/ml) were incubated with 7.28 X  10 -1° M (IX), 2.31  x  10 -l° 
M (r]),  or 7.75  x  10 -II  M (O)  1~SI-GM-CSF at  37°C.  At the time points indicated, aliquots 
were removed and assayed  for binding as described in Materials and  Methods.  Nonspecific 
binding was  measured  in the presence of a  100-fold molar excess of unlabeled GM-CSF at 
each concentration  of ~251-GM-CSF. The continuous  curves passing through  the data  were 
calculated from  the best-fit parameter  values using a  single exponential term (14).  Infinite 
time binding and association rate constants for each curve were, respectively: A, 117.5  +  3.5 
molecules/cell and  8.5 +  0.7  ×  10-2/M.min; ff], 84.4  +  4.8  molecules/cell and  6.9 ±  1.0  x 
10-2/M.min;  ©,  50.8  ±  3.3  molecules/cell and  4.5  ±  0.6  x  10-2/M.min.  A  plot  of the 
association  rate constant calculated from each curve versus the molar concentration of ~251- 
GM-CSF initially present in the medium is shown in the inset (B). (B) Neutrophils (2  x  108 
cells) were incubated with I~SI-GM-CSF (8.2 x  10 -l° M) in  1 ml of binding medium for 30 min 
at 37°C. The cells were then divided, harvested by centrifugation, and resuspended in either 
binding medium alone (O) or binding medium containing 5 x  10 -? M unlabeled GM-CSF (El). 
The cells were maintained at  37°C, and aliquots were removed at various time points and 
assayed for binding. Free ~2~I-GM-CSF concentration during the dissociation incubation was 
1.7 ×  10 -~ M. Error bars on each data point did not exceed the symbol size. 
when  stored  at  4°C  in  0.05  M  NaPO4,  pH  7.2,  containing  0.01%  BSA  and 
0.02%  sodium  azide,  and  they  exhibited  no  changes  in  binding  characteristics 
over  that  time  period.  In  addition,  gel  filtration  chromatography  showed  no 
evidence  of formation  of high  molecular  weight  aggregates  upon  storage. 
Interaction  of GM-CSF with  Cell  Surface  Receptors  on  Neutrophils  and  HL-60 
Cells.  Human  12"~I-GM-CSF  was  shown  to  exhibit  specific  binding  to  human 
neutrophils  and  to  the  promyelocytic  leukemia  cell  line,  HL-60.  Fig.  2A  shows PARK ET  AL  255 
the association kinetics at 37 °C of neutrophils with z25I-GM-CSF at three differ- 
ent concentrations (corrected for nonspecific binding). The data in Fig. 2A show 
that both the final equilibrium amount bound to cells and the rate of approach 
to equilibrium are dependent on the initial concentration of ~25I-GM-CSF in the 
medium.  The  curves  passing  through  the  data  in  Fig.  2A  are  best-fit  single 
exponential time-dependency curves (25), consistent with the presence of a single 
population of receptors on these cells.  In contrast to the rapid binding seen at 
37 ° C, binding at 4 o  C was slow and required > 12 h to reach equilibrium, behavior 
reminiscent of that seen with murine GM-CSF (16, data not shown). 
The inset (Fig.  2B) shows the dependence of the pseudo first-order forward 
rate constant (determined by curve fitting the data of Fig. 2A) on the concentra- 
tion of 125I-GM-CSF in the medium. For a bimolecular reaction such data should 
fit a straight line, with the slope being the forward rate constant and the intercept 
on the ordinate being the reverse rate constant (25). The data shown in the inset 
generate values of 5.5 _+ 2.3 x  107/M.min for the forward rate constant and 4.7 
+  1.0  x  10-2/min for the reverse rate constant. The ratio of these parameters 
gives a  range of values for the affinity constant of the radiolabeled GM-CSF 
preparation for its receptor of 0.6 -  2.1  X 109/M. 
Fig. 2B shows the dissociation of 125I-GM-CSF from neutrophils at 37 ° C. The 
experiment is designed, as originally described by Demeyts et al.  (27),  to test 
whether the GM-CSF receptor exhibits any cooperative properties. Comparison 
of the rate of dissociation of 125I-GM-CSF from cells  in medium alone when a 
fraction of the receptors are occupied, with that in the presence of 5 x  10 -7 M 
unlabeled GM-CSF where  almost all  the  receptors  are  occupied,  revealed  no 
significant sensitivity to receptor occupancy, suggesting that GM-CSF receptors 
on neutrophils are noncooperative. The dissociation rate constants measured in 
this experiment were 2.8  +  0.5  x  10-2/min in medium alone and 1.8  _+ 0.6  x 
10-'~/min in the presence of unlabeled GM-CSF. Since neither curve is a simple 
first-order process,  these values are averages from the sum of two exponential 
terms. While complex dissociation kinetics appear to be generally observed for 
cell  surface  receptor  systems (22,  25,  27-29),  the  cause(s)  for such  behavior 
remain unclear and cannot necessarily be interpreted as indicating site hetero- 
geneity. 
Kinetic experiments with the promyeiocytic leukemia cell line HL-60 showed 
human GM-CSF binding characteristics very similar to those exhibited by human 
neutrophils.  Association and dissociation kinetic experiments generated a  for- 
ward rate constant of 3.05 +  0.43 x  108/M.min and dissociation rate constants 
of 5.0  +  1.3  x  10-2/min  in medium alone and 4.1  +  2.1  x  10-2/min  in  the 
presence of unlabeled GM-CSF. For both HL-60 and neutrophils, we used results 
of association  kinetic  experiments  to  ensure  that,  in  all  subsequent  binding 
experiments, the system had reached equilibrium. These experiments also re- 
vealed  a  strikingly low  number  of GM-CSF  molecules bound  to  the  cells  at 
equilibrium, results that were confirmed by equilibrium binding experiments. 
Fig. 3 illustrates typical equilibrium binding data for 1zSI-GM-CSF at 37 °C to 
neutrophils (Fig. 3 A) and HL-60 cells  (B). In both cases, display of the data in 
the Scatchard coordinate system (30)  yielded a straight line, indicating a single 
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FICuRE  3.  Equilibrium binding of '~51-GM-CSF to neutrophils and HL-60 cel|s. Neutrophils 
(A) and HL-60 (B) (6.7 x  107 cells/ml) were incubated with various concentrations of J25I-GM- 
CSF (specific radioactivity, 8.6 x  1014 cpm/mmol) for 30 min at 37 °C and assayed for binding 
as described in  Materials and  Methods. Data are corrected for nonspecific binding (5.81  x 
10 j° and 2.13  x  10 ~  molecules/cell/M for A and B, respectively), measured in the presence 
of a  100-fold molar excess of unlabeled GM-CSF. The insets show Scatchard representations 
of specific binding replotted from A and B. Curve fitting was done as described in Materials 
and Methods. Error bars on each data point did not exceed the symbol size. 
for binding measured over a concentration range of 10 pM to 10 nM. Nonspecific 
binding increased linearly with increasing concentration and did not exceed 2% 
of the total cpm added. For neutrophils, the calculated apparent Ka was 2.47  + 
1.31  x  10~/M with 260  +  70 specific binding sites per cell (average from seven 
binding experiments), and for HL-60 cells  the calculated apparent K, was 3.70 
+  1.44 x  109/M with 167  _+ 87 specific binding sites per cell (average from six 
binding experiments). Similar experiments with neutrophils carried out at 4°C 
(allowing 18  h  to reach equilibrium) showed an apparent Ka of 2.18  -+ 0.19  x 
109/M with 240  +  60 specific binding sites per cell, indicating that when given 
sufficient time to reach equilibrium the parameters for human GM-CSF binding 
were the same at 37°C as at 4°C. 
To assess  whether  the  affinities of labeled and  unlabeled  GM-CSF  for  the 
receptor were significantly different, the inhibition of binding of ~zSI-GM-CSF 
to neutrophils at 37 °C by unlabeled GM-CSF was determined (data not shown). 
Analysis of the data with a single-site competitive inhibition equation (26) yielded 
an  inhibition  constant  of  1.48  +  0.53  x  10~°/M,  indicating  that  while  not 
substantial,  radiolabeling  of GM-CSF  produced  some  loss  in  affinity for  the 
receptor. 















ob  cde  f  gh  ijklmn 
Inhibitor 
FIGURE 4.  Specificity  of  ~25I-GM-CSF  binding  to  neutrophils.  Neutrophils  (6.7  ×  107 
cells/ml) were  incubated  with  ~zS1-GM-CSF (7.5  x  10 -1°  M)  and  the  following unlabeled 
compounds at the concentrations indicated: a, none; b,  recombinant human GM-CSF, 7.5 x 
g  7  10-  M; c, recombinant murine GM-CSF, 7.5 ×  10-  M; d, CSF-2a, 2.5 ×  10 -a M; e, human 
rIL-2, 6.2  x  10 -8 M;f, human IL-1,  7.4 X  10  -8 M; g, epidermal growth factor, 3 #g/ml; h, 
fibroblast growth factor, 1 ttg/ml; i, nerve growth factor, 2 #g/ml;j, insulin, 1.1 x  10 -7 M; k, 
luteinizing hormone (human), 1 #g/ml; l, growth hormone (human), 1.7 x  10  -7 M; m, thyroid- 
stimulating hormone,  1  #g/ml;  n,  follicle-stimulating  hormone,  1  #g/ml.  Concentrations of 
partially pure hormone preparations are given in #g/ml total protein. Incubation was for 30 
rain at 37°C and binding was assayed as described in Materials and Methods. 
purified lymphokines and other polypeptide hormones for their ability to com- 
pete with  125I-GM-CSF for binding to its receptor on both neutrophils and HL- 
60 cells.  As  shown  in  Fig.  4,  a  l O-fold excess of recombinant human  GM-CSF 
eliminated  65%  of human  125I-GM-CSF  binding  (Fig.  4b),  while  none  of the 
other  lymphokines or hormones  tested,  including  murine  GM-CSF,  exhibited 
any ability to compete, even when present at concentrations that were  100-fold 
greater  (on  a  molar  basis)  than  those  of  125I-GM-CSF (Fig.  4,  c-n).  Identical 
results were found for competition of ]e5I-GM-CSF binding to HL-60 cells (data 
not shown). 
Cellular Distribution of Human GM-CSF Receptors.  A  number of primary cells 
and  continuous  cell  lines  of mouse or human  origin  were  examined for their 
ability  to  bind  125I-GM-CSF.  In  all  cases,  complete binding  curves were  done 
over a range of ]25I-GM-CSF concentrations, and affinity constants and receptor 
numbers per cell were generated by Scatchard analysis of the data. As shown in 
Table I, none of the murine cells tested bound any ]25I-labeled human GM-CSF, 
although all had been previously shown to bind murine GM-CSF (16). In addition 
to neutrophils and  HL-60 cells, only monocytes and the myelogenous leukemia 
line KG-1  of the human  cells tested  were found to bind detectable amounts of 
human GM-CSF. A similar low receptor number was found on all four cell types. 
Although  two cells of T  cell origin  had  been previously found to bind  murine 
GM-CSF  (16),  none of the human  T  cell lines tested exhibited any binding  of 
human GM-CSF. 258  GRANULOCYTE/MACROPHAGE  COLONY-STIMULATING  FACTOR  RECEPTOR 
TABLE  I 
Cellular Distribution  of Human GM-CSF Receptors 
HuGM-CSF bound 
Cells  Characteristics  (molecules/cell)* 
Human 
HL-60  Promyelocytic leukemia  167 _  87 
KG-1  Myelogenous leukemia  170 _+ 80 
U937  Monocytic tumor  0 
K562  Erythroleukemia  0 
CEM  T  lymphoma  0 
HSB-2  T  lymphoma  0 
JMB-12  T  lymphoma  0 
JA-1 (Jurkat)  T  lymphoma  0 
RPMI-8402  T  lymphoma  0 
PEER  T  leukemia  0 
A375  Myeloma  0 
BMB  B lymphoma  0 
Neutrophils  260 +  70 
Monocytes  450 -+ 75 
Mouse 
P388D~  Macrophage tumor  0 
J774  Macrophage tumor  0 
P815  Mastocytoma (ascites)  0 
Wehi 3  Myelomonocyte tumor  0 
LSTRA  T  lymphocytic leukemia  0 
LBRM-33  T  lymphoma  0 
Neutrophils  0 
* Binding experiments were conducted as described in the legend to Fig. 3. 
Discussion 
Recombinant  human  GM-CSF  was  radiolabeled  with  ~25I to  high  specific 
activity, and was used to characterize the specific receptor for this lymphokine 
on human neutrophils and on the promyelocytic leukemia cell  line, HL-60. We 
also found that GM-CSF receptors were expressed on human monocytes and on 
the myelogenous leukemia cell  line, KG-1.  None of the murine cells  tested, all 
of which express routine GM-CSF receptor (16),  was found to bind detectable 
levels of human GM-CSF. This again confirms the lack of crossreactivity between 
the GM-CSFs from these two species. 
As has been  found for three of the routine colony-stimulating factors, GM- 
CSF (15,  16), G-CSF (31),  and CSF-2~ (32,  33),  the level of expression of GM- 
CSF binding sites on the human cells tested was strikingly low, indicating that 
human GM-CSF can exert its biological effects with few molecules bound per 
cell.  All the murine CSFs are active in stimulating cell proliferation and colony 
formation at  10-1~-10 -~3  M concentrations (3),  and a  similar concentration of 
recombinant human  GM-CSF  has  been  found to  be  sufficient to  induce  the 
formation of granulocyte and  macrophage  colonies in  a  human  colony assay 
(unpublished observations).  Binding studies showed that the affinity of human 
GM-CSF for its receptor was 109-101°/M, thus making the concentration of GM- 
CSF required to produce 50% maximal receptor occupancy 10-9--10 -1° M. These 
concentrations are two to three orders of magnitude higher than those required PARK  ET  AL.  259 
to  produce  biological  effects,  indicating  that  only  a  small  component  of the 
detectable  binding  is  required  for  maximal  biological  activity.  These  results 
parallel  those previously reported  for murine  GM-CSF (15,  16),  IL-3  (32-34), 
and the lymphokine,  human  IL-1  (35), and are reminiscent  of other systems in 
which  only  fractional  receptor  occupancy  is  required  to  produce  a  maximal 
biological effect (26). 
As previously discussed (16), these three factors also share a common complex 
pattern  of ligand  dissociation,  in  which  a  slowly exchanging  component  was 
observed which  might  reflect a  subpopulation  of receptors that  can  effectively 
bind ligand irreversibly. As shown in this paper, the dissociation of ~25I-GM-CSF 
from  human  neutrophils  exhibits  a  similar  slowly exchanging  (or  irreversible) 
component.  Whether or not this apparently irreversible interaction  is primarily 
responsible for the capacity of these lymphokines to produce biological effects at 
such low levels of receptor expression, as has been previously suggested (16), is 
not  known,  but the  similarities  between them  suggest  that  they may all  share 
common mechanisms of receptor action. 
GM-CSF can not only stimulate the proliferation and differentiation  of gran- 
ulocyte-macrophage precursor cells, but can modulate the functional activity of 
mature granulocytes and  macrophages as well.  Alterations in the binding char- 
acteristics of the GM-CSF receptor, possibly in a maturation-dependent  manner, 
could explain the different biological effects mediated by this hormone. In their 
report on the murine  GM-CSF receptor,  Walker and  Burgess (15) have in fact 
suggested that the small subclass of high-affinity binding sites that they observe 
may decline in concert with cell maturation.  In our previous study with recom- 
binant  murine  GM-CSF, we found only a  single class of high affinity receptors 
on all  cell  types examined  (16).  In  this  study,  using  recombinant  human  GM- 
CSF, we have similarly found a  single class of high-affinity receptors on human 
cells. In addition, we examined in detail the binding characteristics of the receptor 
on  both a  mature  cell  (neutrophils)  and  on an  undifferentiated  promyelocytic 
leukemia cell line (HL-60).  No significant differences in the kinetic parameters 
of receptor-binding  were  seen  between  these  two  cell  types,  suggesting  that 
maturation-specific responses to GM-CSF are not mediated by overt changes in 
the binding characteristics of the hormone for its receptor. 
In addition to the multiple ways that GM-CSF may function in the control of 
the normal physiology of hematopoiesis, GM-CSF and its receptor may also play 
a role in the pathology of leukemia.  Myeloid leukemia cells, for example, cannot 
proliferate autonomously in  vitro,  but will  grow in  the presence of exogenous 
colony-stimulating  factors  (2),  suggesting  that  these  cells  grow  in  response  to 
factors much as do normal hematopoietic cells. Current studies on the expression 
of GM  receptors  on  human  leukemias  indeed  suggest  that  many,  but not all, 
myeloid leukemias express GM-CSF receptor.  Receptor levels are low and some 
leukemia  cells  appear  to  respond  to  recombinant  GM-CSF  (L.  S.  Park,  R. 
Andrews, I. Berstein, and  D.  L.  Urdal,  unpublished data).  Alternatively,  recent 
observations that  some onc  genes are homologous to growth factors or growth 
factor receptors, notably, that the erb bonc gene is homologous to the receptor 
for epidermal growth factor (36) and that the c-fms proto oncogene is related to 
the receptor for CSF-1 (37), intensify the interest in the GM-CSF receptor found 260  GRANULOCYTE/MACROPHAGE  COLONY-STIMULATING  FACTOR  RECEPTOR 
on malignant cells.  Finally, radiolabeled GM-CSF represents a useful reagent for 
describing the surface phenotype of malignant cells,  and the knowledge of the 
GM-CSF receptor gleaned from such studies will expand our understanding of 
hematopoiesis and may contribute to the diagnosis and potential treatment of 
cancer. 
Summary 
~q-labeled recombinant human GM-CSF was used to identify and characterize 
receptors specific for this  lymphokine on  both a  mature primary cell,  human 
neutrophils, and on the undifferentiated promyelomonocytic leukemia cell line, 
HL-60.  Human GM-CSF also bound to primary human monocytes and to the 
myelogenous leukemia cell line, KG-1, but not to any of the murine cells known 
to express the murine GM-CSF receptor.  In addition, although some murine T 
lymphomas can express the GM-CSF receptor, none of the human cell lines of 
T  cell  lineage that we examined bound iodinated human GM-CSF. Binding to 
all cell types was specific and saturable. Equilibrium binding studies revealed that 
on  all  cell  types examined,  GM-CSF  bound  to  a  single  class  of high  affinity 
receptor (100-500  receptors per cell) with a Ka of 109-101°/M.  More extensive 
characterization with neutrophils and  HL-60  cells  showed  that in  both  cases, 
binding of GM-CSF was rapid at 37°C with a slow subsequent dissociation rate 
that  exhibited  marked biphasic  kinetics.  Among a  panel  of lymphokines and 
growth hormones, only human GM-CSF could compete for binding of human 
~25I-GM-CSF to these cells. GM-CSF can not only stimulate the proliferation and 
differentiation of granulocyte/macrophage precursor cells, but can modulate the 
functional activity of mature granulocytes and macrophages as well.  No signifi- 
cant differences in the kinetic parameters of receptor binding were seen between 
mature neutrophils and  the  undifferentiated promyelocytic leukemia cell  line 
HL-60, indicating that maturation-specific responses to GM-CSF are not medi- 
ated  by  overt  changes  in  the  binding characteristics  of the  hormone  for  its 
receptor. 
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